**Supplementary Table:** Baseline characteristics of the study population

|  |  |  |  |
| --- | --- | --- | --- |
|  | **HIV+** | | **HIV-negative\***  **(n=19)** |
| **No**  **Hypertrophy**  **(n=49)** | **Fat Pad Hypertrophy (n=6)** |
| **Age (years)** | 49 (43-55) | 52 (39-55) | 50 (34-56) |
| **Male gender** | 88% | 50% | 74% |
| **African American** | 73% | 67% | 47% |
| **Current smoker** | 55% | 50% | 53% |
| **Body mass index (kg/m2)** | 26 (22-29) | 41 (35-45) | 27 (26-30) |
| **Diabetes** | 1.8% | 0% | 0% |
| **Hypertension** | 53% | 83% | 16% |
| **Estimated GFR (mL/min/1.73m2)** | 88 (76-102) | 94 (86-102) | 84 (73-107) |
| **LDL cholesterol (mg/dL)** | 88 (70-114) | 84 (73-90) | 88 (76-116) |
| **HDL cholesterol (mg/dL)** | 47 (38-60) | 52 (33-54) | 45 (35-58) |
| **Statin use** | 10% | 17% | 5% |
| **Coronary artery calcium >0** | 42% | 50% | 39% |
| **CD4+ T-cell count (cells/µl)** | 685 (440-807) | 706 (681-865) | -- |
| **Nadir CD4+ T-cells (cells/µl)** | 175 (41-308) | 237 (189-291) | -- |
| **HIV-1 RNA <20 copies/ml** | 88% | 83% | -- |

\* None of the HIV-negative participants had fat pad hypertrophy